Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation

Atherosclerosis

Volumn 192, Issue 2, 2007, Pages 266-274

  Wong, Wai Man R ^a   Gerry, Andrew B ^b   Putt, Wendy ^a   Roberts, Jane L ^a   Weinberg, Richard B ^c   Humphries, Steve E ^a   Leake, David S ^b   Talmud, Philippa J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

apoA IV; Atherosclerosis; Conjugated dienes; Copper; Lipid hydroperoxides; Oxidised low density lipoprotein

Indexed keywords

APOLIPOPROTEIN A4; LOW DENSITY LIPOPROTEIN;

AQUEOUS SOLUTION; ARTICLE; BINDING SITE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING;

AMIDINES; ANTIOXIDANTS; APOLIPOPROTEINS A; COPPER SULFATE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MUTAGENESIS, SITE-DIRECTED; OXIDATION-REDUCTION; PROTEIN ISOFORMS;

EID: 34248210635     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.017     Document Type: Article

References (62)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
2. Parthasarathy S., Fong L.G., Otero D., and Steinberg D. Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci USA 84 (1987) 537-540
3. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85 (1988) 2805-2809
4. Frostegard J., Haegerstrand A., Gidlund M., and Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90 (1991) 119-126
5. Mallat Z., and Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 130 (2000) 947-962
6. MRC/BHF, Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled, trial. Lancet 360 (2002) 23-33
7. Stampfer M.J., Hennekens C.H., Manson J.E., et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328 (1993) 1444-1449
8. Carew T.E., Schwenke D.C., and Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84 (1987) 7725-7729
9. Utermann G., and Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Eur J Biochem 99 (1979) 333-343
10. Hayashi H., Nutting D.J., Fujimoto K., et al. Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat. J Lipid Res 31 (1990) 1613-1625
11. Green P.H., Glickman R.M., Saudek C.D., Blum C.B., and Tall A.R. Human intestinal lipoproteins. Studies in chyluric subjects. J Clin Invest 64 (1979) 233-242
12. Ezeh B., Haiman M., Alber H.F., et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 44 (2003) 1523-1529
13. Steinmetz A., and Utermann G. Activation of lecithin cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem (1985) 2258-2264
14. Chen C.H., and Albers J.J. Activation of lecithin cholesteryl acyltransferase by human apolipoproteins E-2, E-3, and A-IV. Biochim Biophys Acta 836 (1985) 279-285
15. Main L.A., Ohnishi T., and Yokoyama S. Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. Biochim Biophys Acta 1300 (1996) 17-24
16. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., and Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 265 (1990) 4266-4272
17. Steinmetz A., Barbaras R., Ghalim N., et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 265 (1990) 7859-7863
18. Dvorin E., Gorder N.L., Benson D.M., and Gotto A.M. Apolipoprotein A-IV: a determinant for binding and uptake of high density lipoproteins by rat hepatocytes. J Biol Chem 261 (1986) 15714-15720
19. Duverger N., Tremp G., Caillaud J.M., et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 273 (1996) 966-968
20. Kronenberg F., Stuhlinger M., Trenkwalder E., et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 36 (2000) 751-757
21. Warner M.M., Guo J., and Zhao Y. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl) 114 (2001) 275-279
22. Ostos M.A., Conconi M., Vergnes L., et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 1023-1028
23. Ferretti G., Bacchetti T., Bicchiega V., and Curatola G. Effect of human Apo AIV against lipid peroxidation of very low density lipoproteins. Chem Phys Lipids 114 (2002) 45-54
24. Recalde D., Ostos M.A., Badell E., et al. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 24 (2004) 756-761
25. Vowinkel T., Mori M., Krieglstein C.F., et al. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 114 (2004) 260-269
26. Boerwinkle E., Visvikis S., and Chan L. Two polymorphisms for amino acid substitutions in the APOA4 gene. Nucl Acids Res 18 (1990) 4966
27. Tenkanen H., Koskinen P., Metso J., et al. A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127. Biochim Biophys Acta 1138 (1992) 27-33
28. Wong W.R., Hawe E., Li L.K., et al. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 92 (2003) 969-975
29. Wong W.R., Stephens J.W., Acharya J., et al. The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease. J Lipid Res 45 (2004) 1565-1571
30. Wilkins G.M., and Leake D.S. The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages. Biochim Biophys Acta 1211 (1994) 69-78
31. Siow R.C., Richards J.P., Pedley K.C., Leake D.S., and Mann G.E. Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. Arterioscler Thromb Vasc Biol 19 (1999) 2387-2394
32. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6 (1989) 67-75
33. el Saadani M., Esterbauer H., el Sayed M., et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 30 (1989) 627-630
34. Ziouzenkova O., Sevanian A., Abuja P.M., Ramos P., and Esterbauer H. Copper can promote oxidation of LDL by markedly different mechanisms. Free Radic Biol Med 24 (1998) 607-623
35. Bowry V.W., Ingold K.U., and Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 288 Pt 2 (1992) 341-344
36. Weinberg R.B., and Spector M.S. Lipoprotein affinity of human apolipoprotein A-IV during cholesterol esterification. Biochem Biophys Res Commun 135 (1986) 756-763
37. Kuzuya M., Yamada K., Hayashi T., et al. Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein. Biochim Biophys Acta 1123 (1992) 334-341
38. Retsky K.L., Chen K., Zeind J., and Frei B. Inhibition of copper-induced LDL oxidation by vitamin C is associated with decreased copper-binding to LDL and 2-oxo-histidine formation. Free Radic Biol Med 26 (1999) 90-98
39. Roland A., Patterson R.A., and Leake D.S. Measurement of copper-binding sites on low density lipoprotein. Arterioscler Thromb Vasc Biol 21 (2001) 594-602
40. Ramos P., Gieseg S.P., Schuster B., and Esterbauer H. Effect of temperature and phase transition on oxidation resistance of low density lipoprotein. J Lipid Res 36 (1995) 2113-2128
41. Garnier J., Osguthorpe D.J., and Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 120 (1978) 97-120
42. Lohse P., Kindt M.R., Rader D.J., and Brewer Jr. H.B. Three genetic variants of human plasma apolipoprotein A-IV. ApoA-IV- 1(Thr347⋯Ser), apoA-IV-0(Lys167⋯Glu,Gln360⋯His), and apoA-IV-3(Glu165⋯Lys). J Biol Chem 266 (1991) 13513-13518
43. Zaiou M., Visvikis S., Gueguen R., Parra H.J., Fruchart J.C., and Siest G. DNA polymorphisms of human apolipoprotein A-IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population. Clin Genet 46 (1994) 248-254
44. Hixson J.E., and Powers P.K. Restriction isotyping of human apolipoprotein A-IV: rapid typing of known isoforms and detection of a new isoform that deletes a conserved repeat. J Lipid Res 32 (1991) 1529-1535
45. von Eckardstein A., Funke H., Schulte M., Erren M., Schulte H., and Assmann G. Nonsynonymous polymorphic sites in the apolipoprotein (apo) A-IV gene are associated with changes in the concentration of apo B- and apo A-I-containing lipoproteins in a normal population. AJHG 50 (1992) 1115-1128
46. Weinberg R.B., Jordan M.K., and Steinmetz A. Distinctive structure and function of human apolipoprotein variant apoA-IV-2. J Biol Chem 265 (1990) 18372-18378
47. Tenkanen H., and Enholm C. Molecular basis for apoA-IV polymorphisms. Ann Med 24 (1992) 47-52
48. Kalant N., McCormick S., and Parniak M.A. Effects of copper and histidine on oxidative modification of low density lipoprotein and its subsequent binding to collagen. Arterioscler Thromb 11 (1991) 1322-1329
49. Patterson R.A., and Leake D.S. Human serum, cysteine and histidine inhibit the oxidation of low density lipoprotein less at acidic pH. FEBS Lett 434 (1998) 317-321
50. Mackness B., Hunt R., Durrington P.N., and Mackness M.I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 1233-1238
51. Anber V., Griffin B.A., McConnell M., Packard C.J., and Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124 (1996) 261-271
52. Esterbauer H., Gebicki J., Puhl H., and Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13 (1992) 341-390
53. Swain J., and Gutteridge J.M. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 368 (1995) 513-515
54. Lamb D.J., and Leake D.S. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett 338 (1994) 122-126
55. Leake D.S., and Rankin S.M. The oxidative modification of low-density lipoproteins by macrophages. Biochem J 270 (1990) 741-748
56. Kritharides L., Jessup W., and Dean R.T. Macrophages require both iron and copper to oxidize low-density lipoprotein in Hanks' balanced salt solution. Arch Biochem Biophys 323 (1995) 127-136
57. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81 (1984) 3883-3887
58. Heinecke J.W. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic Biol Med 32 (2002) 1090-1101
59. Stadler N., Lindner R.A., and Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24 (2004) 949-954
60. Smith C., Mitchinson M.J., Aruoma O.I., and Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 286 Pt 3 (1992) 901-905
61. Fu S., Davies M.J., Stocker R., and Dean R.T. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem J 333 Pt 3 (1998) 519-525
62. Pietzsch J., and Bergmann R. Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of metal catalysed oxidation of proline and arginine residues of low density lipoprotein apolipoprotein B-100 in human atherosclerotic lesions. J Clin Pathol 56 (2003) 622-623